Incorporation of apolipoprotein E into HBV–HCV subviral envelope particles to improve the hepatitis vaccine strategy

Abstract Hepatitis C is a major threat to public health for which an effective treatment is available, but a prophylactic vaccine is still needed to control this disease. We designed a vaccine based on chimeric HBV–HCV envelope proteins forming subviral particles (SVPs) that induce neutralizing anti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Elsa Gomez-Escobar, Julien Burlaud-Gaillard, Clara Visdeloup, Adeline Ribeiro E. Silva, Pauline Coutant, Philippe Roingeard, Elodie Beaumont
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ee22fd30af2043aa8d96fa2f0f897d87
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ee22fd30af2043aa8d96fa2f0f897d87
record_format	dspace
spelling	oai:doaj.org-article:ee22fd30af2043aa8d96fa2f0f897d872021-11-14T12:20:13ZIncorporation of apolipoprotein E into HBV–HCV subviral envelope particles to improve the hepatitis vaccine strategy10.1038/s41598-021-01428-72045-2322https://doaj.org/article/ee22fd30af2043aa8d96fa2f0f897d872021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-01428-7https://doaj.org/toc/2045-2322Abstract Hepatitis C is a major threat to public health for which an effective treatment is available, but a prophylactic vaccine is still needed to control this disease. We designed a vaccine based on chimeric HBV–HCV envelope proteins forming subviral particles (SVPs) that induce neutralizing antibodies against HCV in vitro. Here, we aimed to increase the neutralizing potential of those antibodies, by using HBV–HCV SVPs bearing apolipoprotein E (apoE). These particles were produced by cultured stable mammalian cell clones, purified and characterized. We found that apoE was able to interact with both chimeric HBV–HCV (E1-S and E2-S) proteins, and with the wild-type HBV S protein. ApoE was also detected on the surface of purified SVPs and improved the folding of HCV envelope proteins, but its presence lowered the incorporation of E2-S protein. Immunization of New Zealand rabbits resulted in similar anti-S responses for all rabbits, whereas anti-E1/-E2 antibody titers varied according to the presence or absence of apoE. Regarding the neutralizing potential of these anti-E1/-E2 antibodies, it was higher in rabbits immunized with apoE-bearing particles. In conclusion, the association of apoE with HCV envelope proteins may be a good strategy for improving HCV vaccines based on viral envelope proteins.Elsa Gomez-EscobarJulien Burlaud-GaillardClara VisdeloupAdeline Ribeiro E. SilvaPauline CoutantPhilippe RoingeardElodie BeaumontNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Elsa Gomez-Escobar Julien Burlaud-Gaillard Clara Visdeloup Adeline Ribeiro E. Silva Pauline Coutant Philippe Roingeard Elodie Beaumont Incorporation of apolipoprotein E into HBV–HCV subviral envelope particles to improve the hepatitis vaccine strategy
description	Abstract Hepatitis C is a major threat to public health for which an effective treatment is available, but a prophylactic vaccine is still needed to control this disease. We designed a vaccine based on chimeric HBV–HCV envelope proteins forming subviral particles (SVPs) that induce neutralizing antibodies against HCV in vitro. Here, we aimed to increase the neutralizing potential of those antibodies, by using HBV–HCV SVPs bearing apolipoprotein E (apoE). These particles were produced by cultured stable mammalian cell clones, purified and characterized. We found that apoE was able to interact with both chimeric HBV–HCV (E1-S and E2-S) proteins, and with the wild-type HBV S protein. ApoE was also detected on the surface of purified SVPs and improved the folding of HCV envelope proteins, but its presence lowered the incorporation of E2-S protein. Immunization of New Zealand rabbits resulted in similar anti-S responses for all rabbits, whereas anti-E1/-E2 antibody titers varied according to the presence or absence of apoE. Regarding the neutralizing potential of these anti-E1/-E2 antibodies, it was higher in rabbits immunized with apoE-bearing particles. In conclusion, the association of apoE with HCV envelope proteins may be a good strategy for improving HCV vaccines based on viral envelope proteins.
format	article
author	Elsa Gomez-Escobar Julien Burlaud-Gaillard Clara Visdeloup Adeline Ribeiro E. Silva Pauline Coutant Philippe Roingeard Elodie Beaumont
author_facet	Elsa Gomez-Escobar Julien Burlaud-Gaillard Clara Visdeloup Adeline Ribeiro E. Silva Pauline Coutant Philippe Roingeard Elodie Beaumont
author_sort	Elsa Gomez-Escobar
title	Incorporation of apolipoprotein E into HBV–HCV subviral envelope particles to improve the hepatitis vaccine strategy
title_short	Incorporation of apolipoprotein E into HBV–HCV subviral envelope particles to improve the hepatitis vaccine strategy
title_full	Incorporation of apolipoprotein E into HBV–HCV subviral envelope particles to improve the hepatitis vaccine strategy
title_fullStr	Incorporation of apolipoprotein E into HBV–HCV subviral envelope particles to improve the hepatitis vaccine strategy
title_full_unstemmed	Incorporation of apolipoprotein E into HBV–HCV subviral envelope particles to improve the hepatitis vaccine strategy
title_sort	incorporation of apolipoprotein e into hbv–hcv subviral envelope particles to improve the hepatitis vaccine strategy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/ee22fd30af2043aa8d96fa2f0f897d87
work_keys_str_mv	AT elsagomezescobar incorporationofapolipoproteineintohbvhcvsubviralenvelopeparticlestoimprovethehepatitisvaccinestrategy AT julienburlaudgaillard incorporationofapolipoproteineintohbvhcvsubviralenvelopeparticlestoimprovethehepatitisvaccinestrategy AT claravisdeloup incorporationofapolipoproteineintohbvhcvsubviralenvelopeparticlestoimprovethehepatitisvaccinestrategy AT adelineribeiroesilva incorporationofapolipoproteineintohbvhcvsubviralenvelopeparticlestoimprovethehepatitisvaccinestrategy AT paulinecoutant incorporationofapolipoproteineintohbvhcvsubviralenvelopeparticlestoimprovethehepatitisvaccinestrategy AT philipperoingeard incorporationofapolipoproteineintohbvhcvsubviralenvelopeparticlestoimprovethehepatitisvaccinestrategy AT elodiebeaumont incorporationofapolipoproteineintohbvhcvsubviralenvelopeparticlestoimprovethehepatitisvaccinestrategy
_version_	1718429322978525184

Incorporation of apolipoprotein E into HBV–HCV subviral envelope particles to improve the hepatitis vaccine strategy

Ejemplares similares